116 related articles for article (PubMed ID: 36717725)
1. The type I interferon antiviral response in the choroid plexus and the cognitive risk in COVID-19.
Suzzi S; Tsitsou-Kampeli A; Schwartz M
Nat Immunol; 2023 Feb; 24(2):220-224. PubMed ID: 36717725
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
3. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function.
Baruch K; Deczkowska A; David E; Castellano JM; Miller O; Kertser A; Berkutzki T; Barnett-Itzhaki Z; Bezalel D; Wyss-Coray T; Amit I; Schwartz M
Science; 2014 Oct; 346(6205):89-93. PubMed ID: 25147279
[TBL] [Abstract][Full Text] [Related]
4. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
[TBL] [Abstract][Full Text] [Related]
5. USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING.
Karlowitz R; Stanifer ML; Roedig J; Andrieux G; Bojkova D; Bechtel M; Smith S; Kowald L; Schubert R; Boerries M; Cinatl J; Boulant S; van Wijk SJL
Cell Death Dis; 2022 Aug; 13(8):684. PubMed ID: 35933402
[TBL] [Abstract][Full Text] [Related]
6. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
7. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
[TBL] [Abstract][Full Text] [Related]
8. The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer's disease.
Mesquita SD; Ferreira AC; Gao F; Coppola G; Geschwind DH; Sousa JC; Correia-Neves M; Sousa N; Palha JA; Marques F
Brain Behav Immun; 2015 Oct; 49():280-92. PubMed ID: 26092102
[TBL] [Abstract][Full Text] [Related]
9. Type I and III interferon responses in SARS-CoV-2 infection.
Kim YM; Shin EC
Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Type I Interferon Associated Factors and COVID-19 Severity.
Bencze D; Fekete T; Pázmándi K
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142877
[TBL] [Abstract][Full Text] [Related]
11. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
[TBL] [Abstract][Full Text] [Related]
12. ACE2 expression is related to the interferon response in airway epithelial cells but is that functional for SARS-CoV-2 entry?
Scagnolari C; Bitossi C; Viscido A; Frasca F; Oliveto G; Scordio M; Petrarca L; Mancino E; Nenna R; Riva E; De Vito C; Midulla F; Antonelli G; Pierangeli A
Cytokine; 2021 Apr; 140():155430. PubMed ID: 33508651
[TBL] [Abstract][Full Text] [Related]
13. IFN-γ-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair.
Kunis G; Baruch K; Rosenzweig N; Kertser A; Miller O; Berkutzki T; Schwartz M
Brain; 2013 Nov; 136(Pt 11):3427-40. PubMed ID: 24088808
[TBL] [Abstract][Full Text] [Related]
14. An Update on Innate Immune Responses during SARS-CoV-2 Infection.
Zhang Y; Chen S; Jin Y; Ji W; Zhang W; Duan G
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696490
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO.
Wu J; Shi Y; Pan X; Wu S; Hou R; Zhang Y; Zhong T; Tang H; Du W; Wang L; Wo J; Mu J; Qiu Y; Yang K; Zhang LK; Ye BC; Qi N
Cell Rep; 2021 Feb; 34(7):108761. PubMed ID: 33567255
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors.
Kumar A; Ishida R; Strilets T; Cole J; Lopez-Orozco J; Fayad N; Felix-Lopez A; Elaish M; Evseev D; Magor KE; Mahal LK; Nagata LP; Evans DH; Hobman TC
J Virol; 2021 Jun; 95(13):e0026621. PubMed ID: 34110264
[TBL] [Abstract][Full Text] [Related]
17. Activation of Type I and Type II Interferon Signaling in SARS-CoV-2-Positive Thyroid Tissue of Patients Dying from COVID-19.
Poma AM; Basolo A; Bonuccelli D; Proietti A; Macerola E; Ugolini C; Torregrossa L; Alì G; Giannini R; Vignali P; Santini F; Toniolo A; Basolo F
Thyroid; 2021 Dec; 31(12):1766-1775. PubMed ID: 34541878
[No Abstract] [Full Text] [Related]
18. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
[TBL] [Abstract][Full Text] [Related]
19. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.
Galani IE; Rovina N; Lampropoulou V; Triantafyllia V; Manioudaki M; Pavlos E; Koukaki E; Fragkou PC; Panou V; Rapti V; Koltsida O; Mentis A; Koulouris N; Tsiodras S; Koutsoukou A; Andreakos E
Nat Immunol; 2021 Jan; 22(1):32-40. PubMed ID: 33277638
[TBL] [Abstract][Full Text] [Related]
20. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors.
Quarleri J; Delpino MV
Cytokine Growth Factor Rev; 2021 Apr; 58():55-65. PubMed ID: 33608189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
